Oral acyclovir in herpes zoster

Area of Science:

• Virology
• Dermatology
• Infectious Diseases

Background:

• Herpes zoster, commonly known as shingles, is a viral infection caused by the reactivation of the varicella-zoster virus.
• The condition is characterized by a painful rash that develops in a specific dermatome.
• Current treatments aim to alleviate symptoms and reduce complications.

Purpose of the Study:

• To evaluate the efficacy of acyclovir in treating herpes zoster.
• To assess the impact of acyclovir on new lesion formation, healing time, and pain.

Main Methods:

• A double-blind, randomized, placebo-controlled study was conducted.
• Forty-one patients diagnosed with herpes zoster participated.
• Participants received either oral acyclovir (400 mg five times daily for five days) or a placebo.

Main Results:

• Acyclovir significantly reduced the duration of new lesion formation within the affected dermatome (P = 0.049).
• Trends favored acyclovir for reduced new lesion formation outside the dermatome, faster crusting and involution, and diminished acute pain.
• No other statistically significant differences were observed between the acyclovir and placebo groups.

Conclusions:

• Acyclovir demonstrates a statistically significant benefit in limiting the progression of new herpes zoster lesions within the affected dermatome.
• While not reaching statistical significance, acyclovir showed promising trends in improving other clinical outcomes, including pain reduction and healing.
• Further research may be warranted to explore optimal dosing or patient populations for acyclovir in herpes zoster management.